<DOC>
	<DOC>NCT01339481</DOC>
	<brief_summary>The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.</brief_summary>
	<brief_title>A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Subject has rheumatoid arthritis (RA), is both abatacept and belataceptna√Øve, and is an eligible candidate to start a course of treatment with abatacept in accordance with the product label Subject is willing and able to comply with study visits and procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Orencia</keyword>
	<keyword>Abatacept</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Infusion</keyword>
</DOC>